
Opinion|Videos|March 25, 2025
Pharmacist-Led Strategies for Adverse Event Management in mCRC
Experts discuss how pharmacists contribute to managing adverse events and toxicity for patients undergoing metastatic colorectal cancer (mCRC) treatment. They explore the factors influencing patient adherence to third-line therapies and ways pharmacists can improve patient education to enhance adherence to treatment regimens.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- In what ways do pharmacists contribute to managing adverse events and toxicity for patients undergoing mCRC treatment?
- What factors influence patient adherence to third-line therapies for mCRC, and how can pharmacists improve patient education to address these challenges and ensure better adherence to treatment regimens?
Advertisement
Related to this article

A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.

The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.

Incidence of diabetic macular edema and the need for glaucoma surgery were reduced after treatment with glucagon-like peptide-1 receptor agonists.

Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.

TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.

Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.

Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
NEI Director Highlights Pediatric Advances, AI’s Promise in Eye Care
3
GLP-1s Have Protective Benefit Against DME, Glaucoma Surgery
4
Keynote Address Tackles AI’s Role in Health Care, Eye Care
5

